ZA98687B - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number: ZA98687B
Authority: ZA; South Africa
Prior art keywords: pharmaceutical composition; vitamin; product; pyridoxine; folate
Prior art date: 1997-01-28

Application number

ZA98687A

Other languages

English (en)

Inventor

Keith Bridgeman

Original Assignee

Goldshield Pharmaceuticals Lim

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-28

Filing date

1998-01-28

Publication date

1998-09-08

1998-01-28 Application filed by Goldshield Pharmaceuticals Lim filed Critical Goldshield Pharmaceuticals Lim

1998-09-08 Publication of ZA98687B publication Critical patent/ZA98687B/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 4
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 3
DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 3
-1 pyridoxine) Chemical compound 0.000 abstract 3
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
235000019152 folic acid Nutrition 0.000 abstract 2
239000011724 folic acid Substances 0.000 abstract 2
229940011671 vitamin b6 Drugs 0.000 abstract 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
229930003537 Vitamin B3 Natural products 0.000 abstract 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
230000009471 action Effects 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
229960003638 dopamine Drugs 0.000 abstract 1
229940014144 folate Drugs 0.000 abstract 1
229960000304 folic acid Drugs 0.000 abstract 1
229910052742 iron Inorganic materials 0.000 abstract 1
229960003966 nicotinamide Drugs 0.000 abstract 1
235000005152 nicotinamide Nutrition 0.000 abstract 1
239000011570 nicotinamide Substances 0.000 abstract 1
229960003512 nicotinic acid Drugs 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
229940127557 pharmaceutical product Drugs 0.000 abstract 1
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
235000008160 pyridoxine Nutrition 0.000 abstract 1
239000011677 pyridoxine Substances 0.000 abstract 1
230000028327 secretion Effects 0.000 abstract 1
230000032258 transport Effects 0.000 abstract 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
235000019160 vitamin B3 Nutrition 0.000 abstract 1
239000011708 vitamin B3 Substances 0.000 abstract 1
235000019158 vitamin B6 Nutrition 0.000 abstract 1
239000011726 vitamin B6 Substances 0.000 abstract 1
239000011701 zinc Substances 0.000 abstract 1
229910052725 zinc Inorganic materials 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Psychology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

ZA98687A 1997-01-28 1998-01-28 Pharmaceutical composition ZA98687B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9701675.2A GB9701675D0 (en)	1997-01-28	1997-01-28	Composition for the treatment of parkinson's disease

Publications (1)

Publication Number	Publication Date
ZA98687B true ZA98687B (en)	1998-09-08

Family

ID=10806668

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA98687A ZA98687B (en)	1997-01-28	1998-01-28	Pharmaceutical composition

Country Status (9)

Country	Link
US (1)	US6200607B1 (de)
EP (1)	EP0980260B1 (de)
AT (1)	ATE260117T1 (de)
AU (1)	AU741511B2 (de)
DE (1)	DE69821929T2 (de)
ES (1)	ES2217534T3 (de)
GB (1)	GB9701675D0 (de)
WO (1)	WO1998032464A1 (de)
ZA (1)	ZA98687B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6476078B2 (en) *	1999-08-11	2002-11-05	Sepracor, Inc.	Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
ES2187115T3 (es) *	1999-01-20	2003-05-16	Nutricia Nv	Preparado para lactantes.
US7226916B1 (en) *	2000-05-08	2007-06-05	N.V. Nutricia	Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en) *	2000-05-08	2007-04-24	N.V. Nutricia	Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US6620850B2 (en) *	2001-09-19	2003-09-16	University Of Florida	Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
US20050065205A1 (en)	2002-03-07	2005-03-24	Daniel Alkon	Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en)	2002-03-07	2004-11-30	Blanchette Rockefeller Neurosciences Institute	Methods for Alzheimer's Disease treatment and cognitive enhancement
GB0313630D0 (en) *	2003-06-12	2003-07-16	Wwk Trust The	Compositions for the enhanced treatment of depression
TW201206425A (en) *	2004-05-18	2012-02-16	Brni Neurosciences Inst	Treatment of depressive disorders
US20070054890A1 (en)	2005-07-29	2007-03-08	Alkon Daniel L	Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
US8367121B2 (en) *	2005-11-23	2013-02-05	Florida A & M University	Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
EP3332797A3 (de)	2007-02-09	2018-08-01	Blanchette Rockefeller Neurosciences Institute	Therapeutische wirkungen von bryostatinen, bryologen und anderen damit zusammenhängenden substanzen auf durch kopftraumata herbeigeführte gedächtnisstörungen und hirnverletzungen
JP5098051B2 (ja)	2007-04-05	2012-12-12	Ｓｂｉファーマ株式会社	ミトコンドリア障害脳疾患治療剤及び診断剤
US9463186B2 (en)	2013-04-15	2016-10-11	Northwestern University	Treatment for dopaminergic disorders
EP3431491A1 (de) *	2017-07-18	2019-01-23	Centre National De La Recherche Scientifique	Verfahren zur reinigung von proteinen mit einer tubulin-carboxypeptidase-aktivität und peptidbasierten inhibitoren davon
US11690849B2 (en)	2019-04-12	2023-07-04	LA PharmaTech Inc.	Method of treating dementia
US11744833B2 (en)	2019-04-12	2023-09-05	LA PharmaTech Inc.	Pharmaceutical compositions and methods for treatment of insomnia
US11351179B1 (en)	2021-08-05	2022-06-07	LA PharmaTech Inc.	Pharmaceutical compositions and methods for treatment of psychiatric disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4167564A (en) *	1974-09-23	1979-09-11	Albion Laboratories, Inc.	Biological assimilation of metals
JPS58162515A (ja) *	1982-03-19	1983-09-27	Tanabe Seiyaku Co Ltd	末梢静脈注入用加電解質アミノ酸輸液
RO94381B1 (ro) *	1986-04-28	1988-05-01	Valentin Stroescu	Produs medicamentos pentru sustinerea efortului de durata medie si lunga
FR2617711B1 (fr) *	1987-07-09	1991-01-04	Mouret Jacques	Application de la l-tyrosine pour l'obtention de medicaments destines au traitement des deficits en dopamine dans les narcolepsies et les depressions dopamino-dependantes
US5122461A (en) *	1990-11-19	1992-06-16	Industrial Technology Research Institute	Preparation of pyrocatecholic compounds
GB2268871A (en) *	1992-07-04	1994-01-26	Bio Nutritional Health Service	Composition for use as a food or food supplement
JPH07330583A (ja) *	1994-06-03	1995-12-19	Terumo Corp	遊離型グルタミン酸を含有する液状製剤
GB9416921D0 (en) *	1994-08-22	1994-10-12	Conway Gitta C	A nutritional preparation

1997
- 1997-01-28 GB GBGB9701675.2A patent/GB9701675D0/en active Pending
1998
- 1998-01-27 EP EP98901388A patent/EP0980260B1/de not_active Expired - Lifetime
- 1998-01-27 AT AT98901388T patent/ATE260117T1/de not_active IP Right Cessation
- 1998-01-27 AU AU57725/98A patent/AU741511B2/en not_active Ceased
- 1998-01-27 DE DE69821929T patent/DE69821929T2/de not_active Expired - Lifetime
- 1998-01-27 ES ES98901388T patent/ES2217534T3/es not_active Expired - Lifetime
- 1998-01-27 WO PCT/GB1998/000229 patent/WO1998032464A1/en not_active Ceased
- 1998-01-27 US US09/367,851 patent/US6200607B1/en not_active Expired - Lifetime
- 1998-01-28 ZA ZA98687A patent/ZA98687B/xx unknown

Also Published As

Publication number	Publication date
WO1998032464A1 (en)	1998-07-30
AU741511B2 (en)	2001-12-06
US6200607B1 (en)	2001-03-13
ES2217534T3 (es)	2004-11-01
ATE260117T1 (de)	2004-03-15
DE69821929D1 (de)	2004-04-01
EP0980260A1 (de)	2000-02-23
AU5772598A (en)	1998-08-18
GB9701675D0 (en)	1997-03-19
EP0980260B1 (de)	2004-02-25
DE69821929T2 (de)	2004-11-11

Publication	Publication Date	Title
GB9701675D0 (en)	1997-03-19	Composition for the treatment of parkinson's disease
NZ334124A (en)	2000-10-27	Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
GEP20053501B (en)	2005-05-10	Core Tablet for Controlled Release of Gliclazide after Oral Administration
MY125978A (en)	2006-09-29	Admantane derivatives
PL340890A1 (en)	2001-03-12	Adamantane derivatives
PL340906A1 (en)	2001-03-12	Adamantane derivatives
AP9801392A0 (en)	1998-12-31	Concentrated antibody preparation.
ZA200501082B (en)	2007-01-31	Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
EP1219622A3 (de)	2003-03-12	Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
EP1259240B8 (de)	2007-05-09	Mittel, wie nikotinamide oder cadpr zur behandlung von hautkrankheiten
BG104877A (en)	2001-06-29	N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
IL113566A0 (en)	1995-08-31	Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
GB2373726B (en)	2004-10-20	Pharmaceutical formulations containing zolmitriptan
WO2003031447A3 (de)	2003-08-28	Pyrimidinderivate mit pde-v hemmender wirkung
IT1222395B (it)	1990-09-05	Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
MY130445A (en)	2007-06-29	Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
WO2003009835A3 (en)	2003-08-07	Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
MY136976A (en)	2008-12-31	Novel use of (r)-(-)-2-[5-(4- flourophenyl) -3-pyridylmethylaminomethyl]- chromane and its physiologically acceptable salts
HRP20000704B1 (hr)	2009-11-30	Peroralni pripravci koji kontrolirano oslobađaju levosimendan
PT1161254E (pt)	2008-03-20	Tratamento de doenças auto-imunes com extracto de ginseng americano
IL164763A0 (en)	2005-12-18	Byperforin derivatives, the use thereof and formulations containing them
IL160160A0 (en)	2004-07-25	SUBSTITUTED 5,6,6a, 11b-TETRAHYDRO-7-OXA-5-AZA-BENZO[c]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS
Domiati et al.	1999	The role of Homocysteine, Folic Acid, Vitamin B6, Vitamin B12 in development of coronary heart disease in Lebanon.(c1999)
UA39228C2 (uk)	2001-06-15	Препарат для підвищення життєстійкості організму
MX9707949A (es)	1998-06-30	Peptido-2 semejante al glucagon y su uso terapeutico.